Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Textual) (Details)

v2.4.0.6
Summary of Significant Accounting Policies (Textual) (Details) (USD $)
3 Months Ended 12 Months Ended
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Accounting Policies [Line Items]                        
Net income (loss) $ (15,539,000) $ (2,309,000) $ (5,519,000) $ (7,490,000) $ (5,297,000) $ (2,742,000) $ (5,040,000) $ (3,471,000) $ (30,857,000) $ (16,550,000) $ (8,541,000)  
Net cash provided by (used in) operating activities                 (11,892,000) (490,000) (16,383,000)  
Accumulated deficit (215,556,000)       (184,699,000)       (215,556,000) (184,699,000)    
Cash and cash equivalents 32,003,000       25,762,000       32,003,000 25,762,000 72,396,000 31,785,000
Translation adjustment included in accumulated other comprehensive income (loss)                 1,000 165,000    
Additional revenue related to prior years as a result of a chance in estimate       1,000,000                
Cash, Cash Equivalents and Marketable Securities [Abstract]                        
Recorded impairment in condensed consolidated statement of operations as sales, general and administrative expenses                 0      
Realized gains (losses) from sales of marketable securities                 0 0 0  
Change in Restricted Cash                 0 45,000 735,000  
Accounts Receivable, Net [Abstract]                        
Allowance for doubtful accounts 150,000       17,000       150,000 17,000    
Accounts written off against the allowance for doubtful accounts                 0 12,000 0  
Advertising [Abstract]                        
Advertising Expense                 351,000 113,000 55,000  
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Undiscounted cash flows, capitalization factor (percent) 625.00%               625.00%      
CO2 Solutions [Member]
                       
Cash, Cash Equivalents and Marketable Securities [Abstract]                        
Recorded impairment in condensed consolidated statement of operations as sales, general and administrative expenses                 800,000      
Accounts Receivable [Member] | Pharmaceutical Customer A [Member]
                       
Concentration of Credit Risk [Abstract]                        
Customer concentration risk (percentage)                 53.00% 1.00%    
Accounts Receivable [Member] | Pharmaceutical Customer B [Member]
                       
Concentration of Credit Risk [Abstract]                        
Customer concentration risk (percentage)                 11.00% 0.00%    
Sales Revenue, Services, Net [Member] | Shell [Member]
                       
Concentration of Credit Risk [Abstract]                        
Customer concentration risk (percentage)                 51.00% 51.00% 62.00%  
Sales Revenue, Services, Net [Member] | Merk [Member]
                       
Concentration of Credit Risk [Abstract]                        
Customer concentration risk (percentage)                 13.00% 10.00% 10.00%  
Prepaid Expenses and Other Current Assets [Member]
                       
Accounting Policies [Line Items]                        
Deferred cost of sales 1,100,000               1,100,000      
Core IP [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Undiscounted cash flows, discount rate (percent)                 18.00%      
Undiscounted cash flows, long-term growth rate (percent)                 2.00%      
Estimated residual value $ 72,300,000               $ 72,300,000      
Percentage of undiscounted cash flows greater than the carrying value of the asset group (percent) 14.00%               14.00%      
Core IP [Member] | Core Pharmaceutical Business [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Undiscounted cash flows, expected percentage of revenue (percent) 69.00%               69.00%      
Core IP [Member] | Enzyme Opportunities [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Undiscounted cash flows, expected percentage of revenue (percent) 31.00%               31.00%      
Core IP [Member] | CodeXyme [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Percentage of undiscounted cash flows per product (percent) 11.00%               11.00%      
Core IP [Member] | CodeXol [Member]
                       
Intangible Assets, Net (Excluding Goodwill) [Abstract]                        
Percentage of undiscounted cash flows per product (percent) 27.00%               27.00%